don’t have a list
of ingredients.

Aimmune is developing desensitization treatments to protect people with food allergies by potentially making accidental exposures less dangerous. Learn More

CODIT™ & Oral Immunotherapy

Aimmune is developing treatments for food allergies using biologic product candidates and our characterized oral desensitization immunotherapy (CODIT™) approach. We built CODIT on a foundation of extensive independent scientific research on oral immunotherapy that shows that patients with food allergies may become desensitized by ingesting their allergens in gradually increasing amounts and then maintaining a steady daily dose thereafter. We aim to offer characterized biologic products to help protect people with food allergies against life-threatening reactions from accidental exposures.

Learn More

AR101 for Peanut Allergy

We are conducting Phase 3 studies of our lead product candidate, AR101, for the treatment of peanut allergy, one of the most common food allergies, in peanut-allergic patients ages 4-55 years in the United States, Canada and Europe. We are also working to develop treatments for other common food allergies using characterized biologic product candidates and our CODIT™ approach.

Learn More